Jose Antonio Ortega
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jose Antonio Ortega has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Cavalli
Computational and Chemical Biology, Istituto Italiano di Tecnologia, Genova, Italy
7 shared publications - Stefania Girotto
Computational and Chemical Biology, Istituto Italiano di Tecnologia, Via Morego 30, 16163 Genova, Italy
4 shared publications - Beatrice Balboni
Computational and Chemical Biology, Istituto Italiano di Tecnologia, Genova, Italy
3 shared publications Bibhas Roy
Laboratory for Nanoscale Biology, Department of Biology and Chemistry, Paul Scherrer Institut, CH-5232 Villigen PSI, Switzerland
3 shared publications- Michel Olivier Steinmetz
Paul Scherrer Institut
3 shared publications - Andrea E. Prota
Laboratory of Biomolecular Research, Division of Biology and Chemistry, Paul Scherrer Institute
2 shared publications
Latest Publications
- Open Access
- 11 March 2024
- Published by Springer Nature in Research Square
Serendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthetic lethality in pancreatic cancer
The innovative framework of a fully small molecule-induced synthetic lethality gained increasing attention for its promising application in the selective eradication of cancer cells. Disrupting the interaction between BRCA2 and RAD51, key players in DNA repair by homologous recombination (HR), represents an interesting option within the synthetic lethality paradigm. We previously showed that combining the PARP inhibitor (PARPi) olaparib with the BRCA2-RAD51 disruptor RS-35d, a racemic dihydroquinolone pyrazoline-derivative previously synthetized by us, was efficient in tackling pancreatic ductal adenocarcinoma (PDAC). To deepen our knowledge on this approach, we investigated RS-35d mode of action by characterising the single contribution of the purified two enantiomers, R-35d and S-35d respectively. RS-35d racemate was unveiled to possess a built-in synthetic lethal profile, falling within the paradigm of “within-pathway synthetic lethality”. This opens the way for novel anticancer synthetic lethality strategies towards more robust personalised medicine approaches for unmet medical needs like BRCA-competent and PARP-resistant PDAC.
- 11 March 2024
- Published by Springer Nature in Research Square
Open AccessSerendipity meets synergism: differential enantiomer activities of a RAD51-BRCA2 disruptor towards a more robust synthetic lethality in pancreatic cancer
The innovative framework of a fully small molecule-induced synthetic lethality gained increasing attention for its promising application in the selective eradication of cancer cells. Disrupting the interaction between BRCA2 and RAD51, key players in DNA repair by homologous recombination (HR), represents an interesting option within the synthetic lethality paradigm. We previously showed that combining the PARP inhibitor (PARPi) olaparib with the BRCA2-RAD51 disruptor RS-35d, a racemic dihydroquinolone pyrazoline-derivative previously synthetized by us, was efficient in tackling pancreatic ductal adenocarcinoma (PDAC). To deepen our knowledge on this approach, we investigated RS-35d mode of action by characterising the single contribution of the purified two enantiomers, R-35d and S-35d respectively. RS-35d racemate was unveiled to possess a built-in synthetic lethal profile, falling within the paradigm of “within-pathway synthetic lethality”. This opens the way for novel anticancer synthetic lethality strategies towards more robust personalised medicine approaches for unmet medical needs like BRCA-competent and PARP-resistant PDAC.
- Open Access
- 20 November 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (51)
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
DNA repair protein RAD51 is a key player in the homologous recombination pathway. Upon DNA damage, RAD51 is transported into the nucleus by BRCA2, where it can repair DNA double‐strand breaks. Due to the structural complexity and dynamics, researchers have not yet clarified the mechanistic details of every step of RAD51 recruitment and DNA repair. RAD51 possesses an intrinsic tendency to form oligomeric structures, which make it challenging to conduct biochemical and biophysical investigations. Here, for the first time, we report on the isolation and characterization of a human monomeric RAD51 recombinant form, obtained through a double mutation, which preserves the protein's integrity and functionality. We investigated different buffers to identify the most suitable condition needed to definitively stabilize the monomer. The monomer of human RAD51 provides the community with a unique biological tool for investigating RAD51‐mediated homologous recombination, and paves the way for more reliable structural, mechanistic, and drug discovery studies.
- 20 November 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (51)
Open AccessIsolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
DNA repair protein RAD51 is a key player in the homologous recombination pathway. Upon DNA damage, RAD51 is transported into the nucleus by BRCA2, where it can repair DNA double‐strand breaks. Due to the structural complexity and dynamics, researchers have not yet clarified the mechanistic details of every step of RAD51 recruitment and DNA repair. RAD51 possesses an intrinsic tendency to form oligomeric structures, which make it challenging to conduct biochemical and biophysical investigations. Here, for the first time, we report on the isolation and characterization of a human monomeric RAD51 recombinant form, obtained through a double mutation, which preserves the protein's integrity and functionality. We investigated different buffers to identify the most suitable condition needed to definitively stabilize the monomer. The monomer of human RAD51 provides the community with a unique biological tool for investigating RAD51‐mediated homologous recombination, and paves the way for more reliable structural, mechanistic, and drug discovery studies.
- Open Access
- 20 November 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (51) , e202312517
Isolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
DNA repair protein RAD51 is a key player in the homologous recombination pathway. Upon DNA damage, RAD51 is transported into the nucleus by BRCA2, where it can repair DNA double‐strand breaks. Due to the structural complexity and dynamics, researchers have not yet clarified the mechanistic details of every step of RAD51 recruitment and DNA repair. RAD51 possesses an intrinsic tendency to form oligomeric structures, which make it challenging to conduct biochemical and biophysical investigations. Here, for the first time, we report on the isolation and characterization of a human monomeric RAD51 recombinant form, obtained through a double mutation, which preserves the protein's integrity and functionality. We investigated different buffers to identify the most suitable condition needed to definitively stabilize the monomer. The monomer of human RAD51 provides the community with a unique biological tool for investigating RAD51‐mediated homologous recombination, and paves the way for more reliable structural, mechanistic, and drug discovery studies.
- 20 November 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (51) , e202312517
Open AccessIsolation and Characterization of Monomeric Human RAD51: A Novel Tool for Investigating Homologous Recombination in Cancer
DNA repair protein RAD51 is a key player in the homologous recombination pathway. Upon DNA damage, RAD51 is transported into the nucleus by BRCA2, where it can repair DNA double‐strand breaks. Due to the structural complexity and dynamics, researchers have not yet clarified the mechanistic details of every step of RAD51 recruitment and DNA repair. RAD51 possesses an intrinsic tendency to form oligomeric structures, which make it challenging to conduct biochemical and biophysical investigations. Here, for the first time, we report on the isolation and characterization of a human monomeric RAD51 recombinant form, obtained through a double mutation, which preserves the protein's integrity and functionality. We investigated different buffers to identify the most suitable condition needed to definitively stabilize the monomer. The monomer of human RAD51 provides the community with a unique biological tool for investigating RAD51‐mediated homologous recombination, and paves the way for more reliable structural, mechanistic, and drug discovery studies.
- 16 July 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 241, 114614
Novel fragment-derived colchicine-site binders as microtubule-destabilizing agents
- 16 July 2022
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 241, 114614
Novel fragment-derived colchicine-site binders as microtubule-destabilizing agents
- Open Access
- 25 April 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (25)
Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
- 25 April 2022
- Published by Wiley in Angewandte Chemie
- Vol. 134 (25)
Open AccessRational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
- Open Access
- 25 April 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (25) , e202204052
Rational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
- 25 April 2022
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 61 (25) , e202204052
Open AccessRational Design of a Novel Tubulin Inhibitor with a Unique Mechanism of Action
In this study, we capitalized on our previously performed crystallographic fragment screen and developed the antitubulin small molecule Todalam with only two rounds of straightforward chemical synthesis. Todalam binds to a novel tubulin site, disrupts microtubule networks in cells, arrests cells in G2/M, induces cell death, and synergizes with vinblastine. The compound destabilizes microtubules by acting as a molecular plug that sterically inhibits the curved‐to‐straight conformational switch in the α‐tubulin subunit, and by sequestering tubulin dimers into assembly incompetent oligomers. Our results describe for the first time the generation of a fully rationally designed small molecule tubulin inhibitor from a fragment, which displays a unique molecular mechanism of action. They thus demonstrate the usefulness of tubulin‐binding fragments as valuable starting points for innovative antitubulin drug and chemical probe discovery campaigns.
- 16 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 229, 114054
ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders
- 16 December 2021
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 229, 114054
ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders